STC1 and glaucoma: In summary, transgene expression of the peptide hormone STC-1 represents a novel approach to sustained IOP reduction therapy that may provide a safe and effective treatment strategy for the 80 million worldwide affected by glaucoma that does not require the use of the FP receptor or a drug elution scaffold for IOP reduction.